ライフサイエンスコーパス: guanylate cyclase

1 s a vital ANF signal transducer motif of the guanylate cyclase.

2 ers include the mammalian NO sensor, soluble guanylate cyclase.

3 capability to the regulatory site in soluble guanylate cyclase.

4 at are not affected by inhibitors of soluble guanylate cyclase.

5 on of NO synthase or the NO receptor soluble guanylate cyclase.

6 nists or inhibitors of nitric oxide (NO) and guanylate cyclase.

7 y interrupts signalling from nitric oxide to guanylate cyclase.

8 differentiated U937 cells that lack soluble guanylate cyclase.

9 an higher apparent affinity with its target guanylate cyclase.

10 ibitors of Gbetagamma, Akt, NOS, and soluble guanylate cyclase.

11 from targeting of the haem moiety of soluble guanylate cyclase.

12 st sensitive target of NO signaling, soluble guanylate cyclase.

13 ivate, and the subsequent generation cGMP by guanylate cyclase.

14 in sepsis and its relationship with soluble guanylate cyclase.

15 fine a new transduction paradigm of membrane guanylate cyclases.

16 cyclic GMP-gated cation channels and distal guanylate cyclases.

17 f the subfamily of Ca(2+)-modulated membrane guanylate cyclases.

18 domains of classical nitric-oxide-regulated guanylate cyclases.

19 protein-coupled receptor kinase 1 (GRK1) and guanylate cyclase 1 (GC1) has been suggested to play a r

20 was to examine the effects of the absence of guanylate cyclase 1 (GC1) on light-driven protein transl

21 ophy caused by loss-of-function mutations in guanylate cyclase 1 (GC1), a key member of the phototran

22 One gene, guanylate cyclase 1 alpha 3 (GUCY1A3), showed differenti

23 Depletion of cGMP by deleting retinal guanylate cyclase 1 or inhibition of PKG using chemical

24 Concomitantly, guanylate cyclase 1, cone T alpha-subunit, cone phosphod

25 ignaling (Nitric Oxide Synthase 3 [NOS3] and Guanylate Cyclase 1, Soluble, Alpha 3 [GUCY1A3]) with a

26 in 2); glucokinase (hexokinase 4) regulator; guanylate cyclase 1, soluble, beta 3; MYST histone acety

27 s (GCAP1 and GCAP2) to their membrane target guanylate cyclase 1.

28 Retinal guanylate cyclases 1 and 2 (GC1 and GC2) are responsible

29 l delivery of AAV5 vectors containing murine guanylate cyclase-1 (GC1) cDNA driven by either photorec

30 function and survival are compromised in the guanylate cyclase-1 (GC1) knockout mouse.

31 Treatment with PKG inhibitor and deletion of guanylate cyclase-1 (GC1), the enzyme producing cGMP in

32 e elucidated this dependency by showing that guanylate cyclase-1 is a novel rhodopsin-binding protein

33 Indeed, we demonstrated that guanylate cyclase-1, producing the cGMP second messenger

34 ons in GUCY2D, the gene that encodes retinal guanylate cyclase-1.

35 peripherin, early growth response 1, soluble guanylate cyclase 1A3 and placental growth factor protei

36 ing identified a single-base substitution in guanylate cyclase 2D, membrane (retina-specific) gene (G

37 -deficient mice (moderate achromatopsia) and guanylate cyclase 2e-deficient mice (LCA with slower con

38 eotide-gated channel B subunit-deficient and guanylate cyclase 2e-deficient mice decreased about 40%

39 roach are the full-length mouse homologue of guanylate cyclase 2F (GUCY2F) and a carboxy-truncated sp

40 eme- and NO-independent activator of soluble guanylate cyclase [4-([(4-carboxybutyl)[2-(5-fluoro-2-([

41 Ongoing clinical trials have found that guanylate cyclase activating peptides are safe and effec

42 ons were made to rods expressing mutant Y99C guanylate cyclase activating protein (GCAP)-1, to unders

43 to show a direct association between RD3 and guanylate cyclase activating protein 1 (GCAP1).

44 three Ca(2+)-binding proteins, recoverin and guanylate cyclase activating proteins 1 (GCAP1) and GCAP

45 Modulated by Ca(2+) sensors guanylate cyclase activating proteins 1 and 2 (GCAP1 and

46 We studied guanylate cyclase-activating protein 1 (GCAP1) as an exa

47 sites (EF-hands) of the GUCA1A gene encoding guanylate cyclase-activating protein 1 (GCAP1) cause slo

48 o the amino acid substitution p.L176F in the guanylate cyclase-activating protein 1 (GCAP1).

49 We tested direct binding of guanylate cyclase-activating proteins (GCAP1 and GCAP2)

50 Guanylate cyclase-activating proteins (GCAPs) are a fami

51 Guanylate cyclase-activating proteins (GCAPs) link cGMP

52 outer segments of GC double knock-out mice, guanylate cyclase-activating proteins 1 and 2, and cycli

53 Treatment with the soluble guanylate cyclase activator BAY41-2272, a vasorelaxing a

54 hodiesterase-5 inhibitors, and now a soluble guanylate cyclase activator have increased therapeutic o

55 Bromo-cGMP, the NO donor SNAP, the guanylate cyclase activator YC-1, and the phosphodiester

56 We show that the guanylate cyclase activator, riociguat, a novel treatmen

57 The guanylate cyclase activator, riociguat, enhanced current

58 as phosphodiesterase (PDE)-5 inhibitors and guanylate cyclase activators may represent a promising t

59 activity kinase that has in vitro kinase and guanylate cyclase activities.

60 l-specific knockout of the ANP receptor with guanylate cyclase activity (betaGC-A-KO).

61 esponses, whereas in Arabidopsis, OsWAKL21.2 guanylate cyclase activity activates these responses.

62 The guanylate cyclase activity and adenylate cyclase activit

63 TNF-alpha also enhanced guanylate cyclase activity and inhibitors of guanylate c

64 guanylate cyclase activity and inhibitors of guanylate cyclase activity blocked the induction of mPGE

65 nding to its extracellular domain stimulates guanylate cyclase activity by an as yet unknown mechanis

66 Blocking soluble guanylate cyclase activity completely suppresses neurite

67 the step is extinguished, and an increase in guanylate cyclase activity during the light step that pe

68 In summary, the loss or gain of guanylate cyclase activity for these NPR1 allelic varian

69 Therefore, the guanylate cyclase activity of BRI1 is modulated by the k

70 sured with suction electrode recordings, and guanylate cyclase activity was measured with the IBMX (3

71 s containing bacterial H-NOX domains exhibit guanylate cyclase activity, but this activity is not inf

72 diazolo[4,3-a]quinoxalin-1-one, a blocker of guanylate cyclase activity.

73 parately, but together the domains exhibited guanylate cyclase activity.

74 an transmembrane receptor carrying intrinsic guanylate cyclase activity.

75 ests additional therapeutic applications for guanylate cyclase agonists.

76 NOS3-/-CSTg), and mice deficient for soluble guanylate cyclase alpha1 (sGCalpha1-/-) were subjected t

77 r inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.

78 sociation of nitric oxide synthase 1/soluble guanylate cyclase and a higher production of cyclic guan

79 ms of CO relied on the activation of soluble guanylate cyclase and calcium-gated potassium channels.

80 inhibition of nitric oxide synthase, soluble guanylate cyclase and cyclo-oxygenase but was blocked by

81 lly part of a larger protein such as soluble guanylate cyclase and in prokaryotes where they are ofte

82 Pharmacological inhibition of soluble guanylate cyclase and NOS activity rapidly induces neuri

83 We investigated the role of downstream guanylate cyclase and phosphodiesterase type 5 (PDE5A) e

84 that requires an atypical O2-binding soluble guanylate cyclase and that is sustained until oxygen lev

85 A canonical Galpha-protein, together with guanylate cyclases and cGMP-gated channels, is needed fo

86 l transduction, namely histidine kinases, di-guanylate cyclases and chemotaxis receptors.

87 litating the stability and/or trafficking of guanylate cyclases and maintaining ER and mitochondrial

88 y NO, CO, and O(2), suggesting that atypical guanylate cyclases and NO-sensitive guanylate cyclases h

89 hemical properties of Gyc-88E are unique for guanylate cyclases and suggest a possible function as an

90 of AxCYTcp, the eukaryotic NO sensor soluble guanylate cyclase, and the ferrocytochrome c/cardiolipin

91 1) Both nitric oxide synthase 1 and soluble guanylate cyclase are expressed in higher levels in vasc

92 Transmembrane guanylate cyclases are also important in gastrointestina

93 Soluble guanylate cyclases are nitric oxide-responsive signaling

94 ide/oxygen-binding (H-NOX) domain of soluble guanylate cyclase as a selective NO sensor.

95 ical and novel NIT-domain containing soluble guanylate cyclases as putative NO/nitrite/nitrate sensor

96 tic peptide receptor B (NPR-B [also known as guanylate cyclase B, GC-B, and GUC2B]; gene name NPR2) p

97 ANF-RGC is the prototype membrane guanylate cyclase, both the receptor and the signal tran

98 mechanism that did not require activation of guanylate cyclase but was mimicked by S-nitroso-glutathi

99 ndothelial nitric-oxide synthase and soluble guanylate cyclase, but direct effects on VEGFR2 have not

100 ted process and requires membrane-associated guanylate cyclases, but not typical phosphodiesterases.

101 In contrast, stimulation of soluble guanylate cyclase by NO yields only a weak and transient

102 Guanylate cyclase C (GC-C) is a transmembrane receptor t

103 Guanylate Cyclase C (GC-C) is an apically-oriented trans

104 osome 12 and then sequenced GUCY2C, encoding guanylate cyclase C (GC-C), an intestinal receptor for b

105 activating mutations in intestinal receptor guanylate cyclase C (GC-C), the genetic cause for the ma

106 Guanylate cyclase C (GUCY2C or GC-C) and its ligands, gu

107 Guanylate cyclase C (GUCY2C) and its hormones guanylin a

108 gous to paracrine hormones of the intestinal guanylate cyclase C (GUCY2C) receptor.

109 in-antagonists, chloride channel activators, guanylate cyclase C agonists, atypical benzodiazepines,

110 out cross-reacting with the human endogenous guanylate cyclase C receptor ligands.

111 a minimally absorbed peptide agonist of the guanylate cyclase C receptor.

112 ylin in the brain and activates the receptor guanylate cyclase-C (GC-C) to reduce food intake and pre

113 n these patients presumably by activation of guanylate cyclase-C (GC-C), which stimulates production

114 naclotide is a minimally absorbed agonist of guanylate cyclase-C (GUCY2C or GC-C) that reduces sympto

115 a minimally absorbed peptide agonist of the guanylate cyclase-C receptor that stimulates intestinal

116 y absorbed, 14-amino acid peptide agonist of guanylate cyclase-C, has shown benefit in a proof-of-con

117 is an active kinase and also encapsulates a guanylate cyclase catalytic centre.

118 Mutating the guanylate cyclase center of PSKR1 impairs seedling growt

119 understanding gastrointestinal transmembrane guanylate cyclase/cGMP physiology has recently accelerat

120 l for therapeutic manipulation of intestinal guanylate cyclase/cGMP signaling for the correction of c

121 enated myoglobin activates canonical soluble guanylate cyclase/cGMP signaling pathways.

122 A guanylate cyclase construct containing the juxta-membran

123 affects the efficacy of soluble/particulate guanylate cyclase coupling to cGMP in cardiac dysautonom

124 tric oxide synthase 1, nitric oxide, soluble guanylate cyclase, cyclic GMP (cGMP), and PKG.

125 f olfactory signal transduction, but express guanylate cyclase-D (GC-D).

126 n did wild-type Brucella or the low-c-di-GMP guanylate cyclase DeltacgsB mutant.

127 o be observed for any member of the membrane guanylate cyclase family.

128 AQP1 is activated by an endogenous receptor guanylate cyclase for atrial natriuretic peptide (ANP).

129 opportunities aimed at activation of soluble guanylate cyclase for multiple cardiovascular indication

130 e a family of proteins that regulate retinal guanylate cyclase (GC) activity in a Ca2+-dependent mann

131 nimals were exquisitely sensitive to NOS and guanylate cyclase (GC) inhibitors (L-NAME, ODQ), which i

132 ein 3 (RD3) is critical in the regulation of guanylate cyclase (GC) signaling and photoreceptor cell

133 studied before and after: (1) inhibition of guanylate cyclase (GC) with and without a NO donor; (2)

134 ls were normal in low-AIPL1 retinas, as were guanylate cyclase (GC), rhodopsin kinase (RK), and norma

135 NO transduces many intracellular signals via guanylate cyclase (GC), we investigated the role of GC,

136 Common downstream effectors of NOS are guanylate cyclase (GC), which synthesizes cyclic GMP, an

137 ny biological effects of NPs are mediated by guanylate cyclase (GC)-coupled NP receptors, NPR-A and N

138 P either by NS-2028 [a specific inhibitor of guanylate cyclase (GC)] or by KT5823 [a specific inhibit

139 Activation of particulate guanylate cyclase (GC-A) by ANP leads to a substantial,

140 Rom1 or peripherin/rds; however, the retinal guanylate cyclases GC1 and GC2 were severely affected in

141 phase of phototransduction by photoreceptor guanylate cyclases (GCs) GC1 (or GC-E) and GC2 (or GC-F)

142 l AWC(ON) behavior, requires a receptor-like guanylate cyclase GCY-28 that acts in adults and localiz

143 The soluble guanylate cyclase GCY-35 is required for high oxygen to

144 ed by tax-2 and tax-4 as well as the soluble guanylate cyclase GCY-35.

145 BAG transduction pathway, the receptor-type guanylate cyclase GCY-9, suffices to confer cellular sen

146 ing of a sensory receptor, the receptor-type guanylate cyclase GCY-9, to cilia in chemosensory neuron

147 ide-gated ion channels and the receptor-type guanylate cyclase GCY-9.

148 The soluble guanylate cyclases GCY-35 and GCY-36, which are expresse

149 channel (tax-4 and tax-2) and transmembrane guanylate cyclases (gcy-8, gcy-18 and gcy-23) eliminated

150 rons counterbalance each other via different guanylate cyclases (GCYs) to control lifespan balance.

151 complex regulates the expression of soluble guanylate cyclase genes and other unidentified genes tha

152 ote cell-type-specific expression of soluble guanylate cyclase genes that have key roles in aggregati

153 gene encoding the alpha subunit of a soluble guanylate cyclase (Gucy1A3).

154 These neurons express the soluble guanylate cyclase Gucy1b2 and the cation channel Trpc2.

155 rtension, riociguat, a stimulator of soluble guanylate cyclase, has proven efficacious.

156 atypical guanylate cyclases and NO-sensitive guanylate cyclases have a common molecular mechanism for

157 tric oxide initiates LTP(GABA) by activating guanylate cyclase in GABA-releasing nerve terminals.

158 than those of dopamine and depend on soluble guanylate cyclase in postsynaptic Kenyon cells.

159 and humans suggests a role for transmembrane guanylate cyclases in intestinal fluid secretion as well

160 ailing the role of a subset of transmembrane guanylate cyclases in the pathophysiology of intestinal

161 by the kinase while cGMP, the product of the guanylate cyclase, in turn inhibits BRI1 kinase activity

162 psis, whereas levels and activity of soluble guanylate cyclase increase.

163 lateral reactions mediated by (*)NO that are guanylate cyclase-independent and rather are dictated by

164 YC-1, an activator of guanylate cyclase, induced mPGES-1.

165 e-treatment of Calu-3 cells with the soluble guanylate cyclase inhibitor 1H-(1,2,4)-oxadiazolo[4,3-a]

166 n of ERK phosphorylation was reversed by the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]q

167 2)O(2)-induced dilation, whereas the soluble guanylate cyclase inhibitor ODQ had no effect.

168 The soluble guanylate cyclase inhibitor oxadiazolo[4,3-alpha]quinoxa

169 Similarly, the guanylate cyclase inhibitors 6-anilino-5,8-quinolinedion

170 sensory neurons, the odorant receptor ONE-GC guanylate cyclase is a central transduction component of

171 d suggest that activation of a receptor-type guanylate cyclase is an evolutionarily conserved mechani

172 is also unknown how binding of NO to heme in guanylate cyclase is communicated to the catalytic domai

173 e (*)NO ligation of the heme iron of soluble guanylate cyclase is consistent with this perspective, t

174 of cyclic guanosine monophosphate (cGMP) by guanylate cyclase is of critical importance to gastroint

175 The guanylate cyclase is the previously characterized ROS-GC

176 receptor ROS-GC1 (rod outer segment membrane guanylate cyclase) is a vital component of phototransduc

177 of mice lacking one of the two NO-sensitive guanylate cyclase isoforms [NO-GC1 knockout (KO) or NO-G

178 iac natriuretic peptides ANP and BNP and the guanylate cyclase-linked natriuretic peptide receptors N

179 ration through activation of the particulate guanylate cyclase-linked natriuretic peptide receptors N

180 itric oxide synthase 1 (and possibly soluble guanylate cyclase) may represent a valuable alternative

181 ly to enhance GABA release through a soluble guanylate cyclase-mediated pathway.

182 Atypical soluble guanylate cyclases mediating O(2) responses also contrib

183 nNOS and its receptor, guanylate cyclase (NO-GC), are expressed in somata of T-

184 xide (NO) activates the NO-sensitive soluble guanylate cyclase (NO-GC, sGC) and triggers intracellula

185 assembled domains of nitric oxide-sensitive guanylate cyclase (NOsGC) remains to be determined.

186 hibited pathological differentiation via the guanylate cyclase NPR2 (natriuretic peptide receptor 2)

187 e current study the conformational change of guanylate cyclase on activation by NO was studied using

188 Our data suggest GLB-5 and the soluble guanylate cyclases operate in close proximity to sculpt

189 , as occurs at the Fe(2+) centres of soluble guanylate cyclase or cytochrome c oxidase.

190 ur through the canonical pathways of soluble guanylate cyclase or protein nitration, but rather throu

191 eraction with specific targets (e.g. soluble guanylate cyclase) or through the generation of secondar

192 cological inhibitors of NO synthase, soluble guanylate cyclase, or cGMP-dependent protein kinases (PK

193 n of COX, but was independent of the soluble guanylate cyclase pathway.

194 iomyocyte cGMP synthesis via an eNOS/soluble guanylate cyclase pathway.

195 ansmitter release from photoreceptors by the guanylate cyclase/PDE6 pair in phototransduction.

196 The homeobox gene Emx1 is expressed in three guanylate cyclase(+) populations, two located in the MOE

197 ncentrations of GTN results in activation of guanylate cyclase, production of cGMP, vasodilation in v

198 rived nitric oxide and activation of soluble guanylate cyclase promotes endothelial quiescence and go

199 generate the NO radical, which can activate guanylate cyclase, react with superoxide, or modify prot

200 ide is a novel therapeutic agent, which is a guanylate cyclase receptor agonist that stimulates water

201 evidence indicates that membrane-associated guanylate cyclase receptors regulate intestinal epitheli

202 d as persistent stimulation of photoreceptor guanylate cyclase, representing a gain of function of mu

203 P2Y12 GPVI, PAR1/PAR4, TP, IP receptors, and guanylate cyclase, respectively, in Factor Xa-inhibited

204 nuated by ODQ, a stimulator and inhibitor of guanylate cyclase, respectively.

205 tients, with associated increases in soluble guanylate cyclase responsiveness to NO.

206 ve recently shown that activation of retinal guanylate cyclase (retGC) by GC-activating proteins (GCA

207 or neutral results), NO-independent soluble guanylate cyclase (sGC) activation, or enhancement of sG

208 Belonging to the class of so-called soluble guanylate cyclase (sGC) activators, cinaciguat and BAY 6

209 nt of a rapid colorimetric assay for soluble guanylate cyclase (sGC) activity adapted for a 96-well m

210 Modulation of soluble guanylate cyclase (sGC) activity by nitric oxide (NO) in

211 in (GTN), resulting in activation of soluble guanylate cyclase (sGC) and cGMP-mediated vasodilation.

212 Epigenetic regulation of soluble guanylate cyclase (sGC) beta1 in breast cancer cells.

213 insertion into the beta1 subunit of soluble guanylate cyclase (sGC) beta1, which enables it to assoc

214 Activation of soluble guanylate cyclase (sGC) by the signaling molecule nitric

215 ges of heme coordination in purified soluble guanylate cyclase (sGC) by time-resolved spectroscopy in

216 Soluble guanylate cyclase (sGC) catalyzes the conversion of guan

217 Soluble guanylyl/guanylate cyclase (sGC) converts GTP to cGMP after bindi

218 Stimulators of soluble guanylate cyclase (sGC) enhance NO signaling; have been

219 RATIONALE: Soluble guanylate cyclase (sGC) heme iron, in its oxidized state

220 G)-nitro-L-arginine methyl ester, or soluble guanylate cyclase (sGC) inhibited by 1H-[1,2,4]oxadiazol

221 uanidine; 10 mumol l(-1) , n = 6) or soluble guanylate cyclase (sGC) inhibitor ODQ (1H-[1,2,4]oxadiaz

222 Soluble guanylate cyclase (sGC) is a heme-containing enzyme that

223 Soluble guanylate cyclase (sGC) is a heterodimer composed of alp

224 Soluble guanylate cyclase (sGC) is a heterodimeric, nitric oxide

225 Soluble guanylate cyclase (sGC) is a nitric oxide- (NO-) sensing

226 The heme cofactor in soluble guanylate cyclase (sGC) is a selective receptor for NO,

227 Soluble guanylate cyclase (sGC) is generally regarded as the pri

228 Soluble guanylate cyclase (sGC) is the mammalian endogenous nitr

229 Soluble guanylate cyclase (sGC) is the primary nitric oxide (NO)

230 Soluble guanylate cyclase (sGC) is the primary receptor for nitr

231 Soluble guanylate cyclase (sGC) is the primary receptor for the

232 the eye; however, the involvement of soluble guanylate cyclase (sGC) is unknown.

233 Soluble guanylate cyclase (sGC) is weakly activated by carbon mo

234 changes in expression of eNOS, iNOS, soluble guanylate cyclase (sGC) or antioxidant genes.

235 s required for activation of NOS and soluble guanylate cyclase (sGC) serves as a NO receptor.

236 Soluble guanylate cyclase (sGC) serves as a receptor for the sig

237 The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recentl

238 YC-1) is an allosteric stimulator of soluble guanylate cyclase (sGC) that sensitizes the enzyme to th

239 hysiological processes by activating soluble guanylate cyclase (sGC) to produce the second messenger

240 Soluble guanylate cyclase (sGC) uses a ferrous heme cofactor as

241 ery pressure encodes an alpha1-A680T soluble guanylate cyclase (sGC) variant.

242 a(cat) and beta(cat)) of alpha1beta1 soluble guanylate cyclase (sGC) were expressed in Escherichia co

243 Soluble guanylyl/guanylate cyclase (sGC), a heme-containing heterodimeric

244 Soluble guanylate cyclase (sGC), a hemoprotein, is the primary n

245 Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxid

246 (ODQ) resulted in heme oxidation of soluble guanylate cyclase (sGC), as evident from diminished NO-i

247 ine the role of a downstream signal, soluble guanylate cyclase (sGC), in the regulation of NHGU by NO

248 rties with the eukaryotic NO-sensor, soluble guanylate cyclase (sGC), including 5c-NO formation via t

249 loss of the prosthetic haem group of soluble guanylate cyclase (sGC), preventing its activation by ni

250 or a related species that activates soluble guanylate cyclase (sGC), resulting in cGMP-mediated vaso

251 be eliminated by inhibiting hepatic soluble guanylate cyclase (sGC), suggesting that the sGC pathway

252 Soluble guanylate cyclase (sGC), the mammalian NO sensor, transd

253 Soluble guanylyl/guanylate cyclase (sGC), the primary biological receptor

254 Regulation of soluble guanylate cyclase (sGC), the primary NO receptor, is lin

255 Soluble guanylate cyclase (sGC), the primary NO receptor, trigge

256 The downstream target of NO, soluble guanylate cyclase (sGC), was in somata in the inner and

257 oxide (NO)-independent activators of soluble guanylate cyclase (sGC), YC-1, and BAY-58-2667 on TM cel

258 unctions as the primary activator of soluble guanylate cyclase (sGC).

259 tion of BAY 60-2770, an activator of soluble guanylate cyclase (sGC).

260 ctivity of the downstream NO target, soluble guanylate cyclase (sGC).

261 through activation of the soluble isoform of guanylate cyclase (sGC).

262 tivator of the mammalian hemoprotein soluble guanylate cyclase (sGC).

263 ide capable of activating the enzyme soluble guanylate cyclase (sGC).

264 nding) family of proteins, including soluble guanylate cyclase (sGC).

265 d neurotransmission by activation of soluble guanylate cyclase (sGC).

266 ) produces its effects by activating soluble guanylate cyclase (sGC).

267 elevant activator of the hemoprotein soluble guanylate cyclase (sGC).

268 ting cGMP signaling cascades through soluble guanylate cyclase (sGC).

269 ing the airway smooth muscle enzyme, soluble guanylate cyclase (sGC).

270 ignaling proteins in cells including soluble guanylate cyclase (sGC).

271 tor component, the alpha1 subunit of soluble guanylate cyclase (sGCalpha1), are prone to hypertension

272 Soluble guanylate cyclases (sGCs) are gas-binding proteins that

273 Significance statement: Soluble guanylate cyclases (sGCs) control essential and diverse

274 vels requires cGMP signaling through soluble guanylate cyclases (sGCs), proteins that bind gases thro

275 lagen-1 production did not depend on MAPK or guanylate cyclase signaling pathways but did depend on t

276 target proteins beta-PIX, plakophilin-4, and guanylate cyclase soluble subunit alpha-2 using colocali

277 ervious pulmonary embolism, treatment with a guanylate cyclase stimulator normalized pulmonary hemody

278 Among patients with HFpEF, the soluble guanylate cyclase stimulator praliciguat, compared with

279 rectomy (PEA) who were receiving the soluble guanylate cyclase stimulator riociguat.

280 ulmonary vasodilator reserve using a soluble guanylate cyclase stimulator, BAY 41-8543.

281 Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase

282 e effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart fai

283 f diabetes status, and vericiguat, a soluble guanylate cyclase stimulator, reduces heart failure hosp

284 efficacy and safety of a novel oral soluble guanylate cyclase stimulator, vericiguat, on quality of

285 hypothesized that riociguat, a novel soluble guanylate cyclase stimulator, would have beneficial hemo

286 member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previo

287 drugs are being evaluated, including soluble guanylate cyclase stimulators, phosphodiesterase type 5

288 sts, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, a

289 ation of GCY-33 and GCY-35, atypical soluble guanylate cyclases that act as O2 sensors, to the dendri

290 liseconds, cGMP is relayed from the receptor guanylate cyclase to a cGMP-gated channel that serves as

291 produce NO, leading to production of cGMP by guanylate cyclase, to transduce the extracellular signal

292 The rod outer segment membrane guanylate cyclase type 1 (ROS-GC1), originally identifie

293 and GCAP2 to the full-length membrane-bound guanylate cyclase type 1.

294 GCAP1-L151F stimulation of photoreceptor guanylate cyclase was not completely inhibited at high p

295 between nitric oxide synthase 1 and soluble guanylate cyclase were determined.

296 GLB-5 acts with the atypical soluble guanylate cyclases, which are a different type of oxygen

297 and apoptosis via activation of Akt1/PKB and guanylate cyclase, while HO-1 gene silencing exacerbated

298 ) production with l-NA (100 mum) and soluble guanylate cyclase with 1H-[1,2,4]oxadiazolo[4,3-a]quinox

299 Inhibition of guanylate cyclase with oxadiazoloquinoxalin (ODQ) also i

300 AP2 bound to different regions on the target guanylate cyclase with submicromolar affinity (apparent